Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.
During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology.
Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.
Funding Rounds (4) - $73.27MUpdate
Current Team (12)Update
|Jun 2, 2016||PRNewswire UK All - LSP Announces $280 Million Final Closing of Life Sciences Venture Fund|
|Jun 1, 2016||Med City News - Morning Read: BioMarin pulls plug on $680M Duchenne drug, Valeant’s Pearson cashes in|
|May 31, 2016||Xconomy - Two Years After Paying $680M, BioMarin Shelves Duchenne Drug|
|Apr 22, 2016||The Street - Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?|
|Mar 10, 2016||Business Insider (tech) - One of the most hated sectors looks like it's setting up for a huge rally|
|Mar 3, 2016||Xconomy - Spurned in Duchenne, BioMarin Will Seek Approval For Batten Drug|
|Jan 16, 2016||Contra Costa Times - FDA denies approval for BioMarin's new drug to treat muscle-wasting disease|
|Jan 14, 2016||Xconomy - FDA Rejects BioMarin’s Duchenne Drug, Sarepta Up Next|
J.H. Oortweg 21 Leiden